Table 1.
ADA Hb1Ac goals in patients with type 2 diabetes
| Variable | HbA1c < 7 | HbA1c > 7 | p | 95% CI | OR |
|---|---|---|---|---|---|
| n | 56 (19.44) | 232 (80.55) | – | – | |
| Age (years) | 56.89 ± 10.62 | 57.99 ± 10.98 | 0.4938c | [-2.07,4.26]a | – |
| Female (%) | 29 (17.68) | 135 (82.32) | 0.472564d | [0.69,2.43] | 1.3 |
| Male (%) | 27 (21.77) | 97 (78.23) | |||
| Insulin Requirement (%) | |||||
| No | 52 (22.13) | 183 (77.87) | |||
| Yes | 4 (7.55) | 49 (92.45) | <0.05a, e | [0.07,0.84] | 0.29 |
| Combination with other ant diabetics (%) | |||||
| Saxaglyptin | 29 (26.85) | 79 (73.15) | <0.05a, d | [1.1,3.92] | 2.08 |
| Sulfonylureas | 10 (30.3) | 23 (69.7) | 0.1495d | [0.78,4.67] | 1.98 |
| Metformin | 38 (23.03) | 127 (76.97) | 0.103d | [0.91,3.44] | 1.75 |
| Pioglitazone | 8 (23.53) | 26 (76.47) | 0.6817d | [0.49,3.24] | 1.32 |
| Acarbose | 6 (21.43) | 22 (78.57) | 0.9777d | [0.36,3.11] | 1.15 |
| Monotherapy | 21 (20.39) | 82 (79.61) | 0.8834d | [0.57,2.08] | 1.1 |
| Sitagliptine | 18 ( 12.59 ) | 125 (87.41) | <0.01b,d | [0.21,0.78] | 0.41 |
| Drug use (%) | |||||
| Statin | 30 (18.75) | 130 (81.25) | 0.854714d | [0.48,1.7] | 0.91 |
| Aspirin | 20 (15.5) | 109 (84.5) | 0.16998 d | [0.32,1.19] | 0.63 |
| Comorbidity (%) | |||||
| Dyslipidemia | 6 (17.65) | 28 (82.35) | 0.959111d | [0.28,2.31] | 0.87 |
| Neuropathy | 0 ( 0 ) | 3 (100) | 0.902737e | [0,10.1] | – |
| Nephropathy | 0 ( 0 ) | 1 (100) | 1e | [0,161.17] | |
95% CI 95% confidence interval; ORodds ratio
aP < 0.05
bP < 0.01
ctwo-sample t-test
dPearson χ2
eFisher´s exact test